Equities

IXICO PLC

IXI:LSE

IXICO PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)8.13
  • Today's Change0.00 / 0.00%
  • Shares traded4.83k
  • 1 Year change-57.79%
  • Beta0.7440
Data delayed at least 20 minutes, as of May 03 2024 13:28 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year IXICO PLC's revenues fell -22.89% from 8.64m to 6.67m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 1.03m to a loss of 1.18m.
Gross margin49.06%
Net profit margin-17.67%
Operating margin-21.56%
Return on assets-8.52%
Return on equity-9.85%
Return on investment-9.57%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at IXICO PLC fell by 1.74m. However, the company earned 302.00k from its operations for a Cash Flow Margin of 4.53%. In addition the company used 1.86m on investing activities and also paid 156.00k in financing cash flows.
Cash flow per share-0.0115
Price/Cash flow per share--
Book value per share0.2364
Tangible book value per share0.1093
More ▼

Balance sheet in GBPView more

IXICO PLC appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.91
Quick ratio--
Total debt/total equity0.0339
Total debt/total capital0.0327
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -219.92%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-225.98
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.